<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142992">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01998984</url>
  </required_header>
  <id_info>
    <org_study_id>LP0105-1020</org_study_id>
    <nct_id>NCT01998984</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis</brief_title>
  <official_title>Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, double-blind, parallel groups, vehicle controlled, 8-week phase 2
      trial. The objective is to evaluate efficacy of ingenol mebutate gel 0.06 % after once daily
      treatment for 2, 3 or 4 consecutive days compared to vehicle gel
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Complete clearance of AKs</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate efficacy of ingenol mebutate gel after once daily treatment for 2, 3 or 4 consecutive days compared to vehicle gel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in AK count</measure>
    <time_frame>From baseline to week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial clearance of AKs</measure>
    <time_frame>From baseline to week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>2 days placebo and 2 days drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 day placebo and 3 days drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 days placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4 days drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ingenol mebutate</intervention_name>
    <arm_group_label>2 days placebo and 2 days drug</arm_group_label>
    <arm_group_label>1 day placebo and 3 days drug</arm_group_label>
    <arm_group_label>4 days drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects with 5 to 20 clinically typical, visible and discrete AKs within a contiguous
        area of approximately 250 cmÂ² sun-damaged skin on either trunk (except chest), or
        extremities

        Exclusion Criteria:

          -  Location of the treatment area (trunk (except chest) or extremities)

               -  within 5 cm of an incompletely healed wound,

               -  within 5 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma
                  (SCC)

          -  Prior treatment with ingenol mebutate within the selected treatment area

          -  Lesions in the treatment area that have:

               -  atypical clinical appearance (e.g., hypertrophic,hyperkeratotic or cutaneous
                  horns) and/or,

               -  recalcitrant disease (e.g., did not respond to cryotherapy on two previous
                  occasions)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel M Siegel, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lond Island Skin Cancer and Dermatologic Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mette K Fife, MSc</last_name>
    <phone>+45 72262445</phone>
    <email>mette.kielsholm@leo-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Long Island Skin Cancer and Dermatologic Surgery</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel M Siegel, MD MS</last_name>
    </contact>
    <investigator>
      <last_name>Daniel M Siegel, MD MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>November 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
